EN DE
STOCK COMPARISON

Blue Jet Healthcare vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Blue Jet Healthcare (BLUEJET) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 13, 2026.

As of Aug 13, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Blue Jet Healthcare trades at ₹587 versus a fair value of ₹263 (-55%), while Vertex Pharmaceuticals trades at $530 versus $279 (-47%).
Blue Jet Healthcare
BLUEJET.NSE · INR · Health Care
-55%
upside to fair value
overvalued
Price₹587
Fair Value₹263
Quality65/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-47%
upside to fair value
overvalued
Price$530
Fair Value$279
Quality79/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Blue Jet HealthcareVertex Pharmaceuticals
Valuation
36.7×P/E (TTM)28.8×
9.61×P/S (TTM)10.06×
8.04×P/B6.59×
30.6×EV/EBITDA23.8×
PEG1.72×
0.2%Dividend yield
₹1.20Dividend per share
Profitability
26%Net margin36%
28%Operating margin38%
20%Return on equity24%
11%Return on assets12%
Growth
-31%Revenue growth (YoY)8%
15.0%Avg. growth/yr (3Y)10.6%
13.9%Avg. growth/yr (5Y)14.2%
Balance & size
Debt / equity0.03×
$956MMarket cap$123B
expensiveGrowth qualityhealthy

Vertex Pharmaceuticals leads: 2 to 9 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Blue Jet Healthcareof which business quality 62 · market factors 47 Vertex Pharmaceuticalsof which business quality 77 · market factors 78
ProfitabilityMargins and returns on capital today
83
72
Quality GrowthAre margins and returns improving?
87
65
CashflowEarnings quality: real cash, not paper profit
8
79
Fin. StrengthBalance sheet, leverage, solvency risk
86
92
InvestmentDisciplined investing over empire-building
23
58
Low VolatilityCalm price path (market factor)
49
86
MomentumPrice trend over the last 3–12 months (market factor)
61
68
52W MomentumDistance to the 52-week high (market factor)
21
86
Net IssuanceBuybacks instead of dilution
82
82

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Blue Jet Healthcare

DCF Models₹392
Earnings-Based₹263
Dividend Discount₹17.60
Multiples₹303
Asset-Based₹43.77
Economic Profit₹213
Growth Earnings₹391

16 of 17 models see the stock below the current price.

Vertex Pharmaceuticals

DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692

21 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Blue Jet Healthcare
Bear ₹122Fair Value ₹263Bull ₹387
₹587 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$530 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Blue Jet Healthcare · Health Care

Quality score65 · Top 25%
Fair value upside-55% · below median

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-47% · below median

Bottom line

As of Aug 13, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Blue Jet Healthcare trades at ₹587 versus a fair value of ₹263 (-55%), while Vertex Pharmaceuticals trades at $530 versus $279 (-47%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.